Share This Article
Perimenopause lasts an average of four years, and for some women closer to eight. It usually begins while periods are still arriving, which is precisely why it goes unrecognized for so long. Symptoms get attributed to stress, to work, to parenting teenagers, to poor sleep. By the time the connection is made, many women have spent years managing something they assumed was simply their new baseline.
The question that follows is harder than it looks: how do you know whether what you are experiencing warrants treatment, and whether hormone therapy is the right treatment for you?
What hormone replacement therapy actually is
Hormone replacement therapy replaces the hormones the ovaries stop producing reliably during the menopausal transition, principally estrogen and progesterone.
Estrogen is the component that treats the symptoms. Progesterone is included for any woman who still has a uterus, because estrogen given on its own causes the uterine lining to thicken over time. Women who have had a hysterectomy generally take estrogen alone.
Testosterone is sometimes added, though its evidence base is narrower than the marketing implies. International consensus supports it for one specific indication, distressing low sexual desire after menopause, and the evidence for using it to treat fatigue or cognitive symptoms is not established.
Delivery formats include skin patches, gels and sprays, tablets, vaginal preparations, and implants. The choice of route is a clinical decision rather than a preference, because the routes carry different risk profiles.
Seven signs you may need hormone replacement therapy
1. Hot flashes and night sweats that disrupt your life. Occasional warmth is one thing. Waking repeatedly, changing bedding, or excusing yourself from meetings is the threshold where treatment becomes a reasonable conversation. Vasomotor symptoms are the indication with the strongest evidence behind hormone therapy.
2. Cycles that have become unpredictable, alongside mood changes. Shorter cycles, then longer ones, then skipped months. When irregularity arrives together with irritability or low mood that feels chemical rather than situational, the two are usually related.
3. Brain fog that was not there before. Difficulty retrieving words, losing the thread mid-sentence, needing lists for things you used to hold in your head. It is a genuinely reported feature of the transition, and for most women it improves rather than progresses.
4. Anxiety or low mood without an obvious cause. New-onset anxiety in the mid-forties, particularly in women with no previous history, deserves consideration in this context rather than an automatic antidepressant.
5. Vaginal dryness, discomfort or pain during sex. This one is underreported and undertreated. Genitourinary syndrome of menopause tends to progress rather than resolve on its own, and local vaginal estrogen treats it with minimal systemic absorption, which makes it appropriate for many women who cannot or prefer not to take systemic therapy.
6. Bone density loss or a fracture from a minor fall. Bone loss accelerates fastest in the years immediately around the final period. A fracture from standing height in your fifties is a signal, not bad luck.
7. Fatigue that sleep does not fix. The least specific symptom on this list, and the one most likely to have another cause entirely, which is exactly why it should be investigated rather than assumed.
None of these justify self-diagnosis. They justify an appointment.
The symptoms that get missed
Two patterns rarely make the standard lists.
Low progesterone in perimenopause. Progesterone often declines before estrogen does, because cycles become anovulatory while estrogen production continues, sometimes erratically. The result is a period of relative estrogen dominance: heavier or more frequent bleeding, breast tenderness, disrupted sleep in the second half of the cycle, and heightened anxiety. Women in this phase are frequently told their estrogen is normal, which it may well be, and sent away.
Late perimenopause. The final stretch before periods stop is when symptoms often peak. Gaps of sixty days or more between periods, hot flashes at their most intense, and the sharpest phase of bone loss. Women who have already been managing symptoms for years sometimes assume the worsening means something has gone wrong. Usually it means the transition is nearing its end.
What a proper hormone evaluation involves
A useful assessment is mostly conversation. Symptoms, their severity and their timing. Menstrual history. Personal and family history, particularly of breast cancer, cardiovascular disease, stroke and clotting disorders. Migraine with aura. Current medications.
Blood testing plays a supporting role, and its limits deserve to be stated plainly. In women over forty-five with typical symptoms, guidelines generally recommend diagnosing perimenopause clinically rather than by hormone levels, because FSH and estradiol fluctuate so widely during the transition that a single measurement can mislead in either direction. Testing has more value in younger women, in those without a uterus, or where the picture is unclear.
What testing does earn its place for is everything that mimics menopause: thyroid function, ferritin and full blood count, vitamin D, and metabolic markers including fasting glucose. Thyroid disease and iron deficiency both produce fatigue, low mood and hair thinning, and both are treated entirely differently. A physician-led approach to hormone replacement therapy typically begins with that full picture rather than a standard prescription, because the decision about whether to treat, and with what, depends on what the rest of the assessment shows.
The forms it comes in
Estrogen-only. For women who have had a hysterectomy. Available as patch, gel, spray or tablet.
Combined estrogen and progestogen. For women with a uterus. Progestogen can be taken orally, combined into a patch, or delivered by a hormonal intrauterine system, which some women prefer because it also manages heavy bleeding.
Vaginal estrogen. Low dose, applied locally, for genitourinary symptoms. Systemic absorption is minimal, and it can be used alongside systemic therapy or on its own.
Body-identical versus compounded. This distinction matters and is routinely blurred. Regulated body-identical preparations, meaning micronized progesterone and estradiol produced to pharmaceutical standards, are approved products with known dosing. Custom-compounded hormone preparations sold as bioidentical are a different category: menopause societies do not recommend them, because purity, dosing consistency and safety monitoring are not assured.
Testosterone. Prescribed off-label in many countries, since female-dose formulations are not licensed everywhere, and appropriate for a narrow indication.
The benefits, stated accurately
For moderate to severe hot flashes and night sweats, hormone therapy is the most effective treatment available. Trials consistently show substantial reduction in frequency and severity, well beyond what has been demonstrated for non-hormonal alternatives.
It prevents bone loss and reduces fracture risk while it is being taken.
It treats genitourinary symptoms, which do not tend to improve without treatment.
Many women report better sleep and steadier mood, though disentangling a direct effect from the effect of no longer waking drenched at three in the morning is difficult in trials.
On cardiovascular health, the evidence supports timing rather than a blanket claim. Major society positions converge on the same point: for healthy women who begin therapy under sixty, or within ten years of their final period, the benefit-risk balance is generally favorable. Starting much later carries a different profile. This is what clinicians mean by the window of opportunity, and it is the strongest argument against waiting to see whether symptoms pass.
What hormone therapy is not is a treatment for the prevention of chronic disease in women without symptoms. That is a different question with a different answer.
The risks, in proportion
Breast cancer. Combined estrogen and progestogen therapy is associated with a small increase in breast cancer risk that rises with duration of use, and declines after stopping. Estrogen-only therapy carries a lower risk, and in some analyses no increase. The absolute numbers are smaller than most women
assume, and they sit in the same range as several lifestyle factors, including regular alcohol consumption and being significantly overweight. Absolute risk, not relative risk, is the number to ask your doctor for.
Blood clots. Oral estrogen is associated with increased venous thromboembolism risk. Transdermal preparations, meaning patches, gels and sprays, bypass first-pass liver metabolism and have not shown the same association, which is why they are usually preferred for women with clotting risk factors, migraine with aura, or a higher BMI.
Stroke. A small increase with oral preparations, again not seen to the same degree with transdermal routes at standard doses.
Women with a personal history of breast cancer, certain clotting disorders, unexplained vaginal bleeding, or active liver disease require specialist input, and for some, hormone therapy will not be appropriate.
The point of listing these is not to alarm. It is that the risk profile depends heavily on which product, which route, what age, and which personal history, which is exactly why a blanket answer about whether hormone therapy is safe cannot be given.
What hormone replacement therapy costs
Cost varies considerably by country and by health system. In the United States, out-of-pocket costs commonly fall somewhere between fifty and two hundred dollars per month depending on the preparation and on insurance coverage, with generic formulations at the lower end. Coverage is inconsistent, and compounded preparations are typically not covered at all.
In systems with public provision or subsidized pharmaceuticals, the figure is often a fraction of that. Cost differences between countries are substantial enough that they influence some women’s decisions about where they seek treatment.
Questions worth asking your doctor
- Based on my personal and family history, am I a reasonable candidate?
- Which route do you recommend for me, and why that one rather than the alternatives?
- What is my absolute risk, in numbers, rather than the relative figures in the headlines?
- How long should I expect to take this, and how will we review it?
- What monitoring will you do, and how often?
- If hormone therapy is not right for me, what are the alternatives with actual evidence behind them?
Frequently asked questions
At what age should I consider it?
Most women begin considering it during perimenopause, typically in their forties or early fifties. Since the benefit-risk balance is most favorable when therapy starts under sixty or within ten years of the final period, waiting for symptoms to resolve on their own has a cost.
Can I take it if I get migraines?
Migraine is not a contraindication. Transdermal preparations are generally preferred, particularly for migraine with aura. This is a conversation to have specifically rather than assume the answer to.
Is there a natural alternative?
Some women get relief from phytoestrogens, cognitive behavioral therapy, which has reasonable evidence for vasomotor symptoms and sleep, and from exercise and reduced alcohol. For moderate to severe
symptoms, these generally do not match hormone therapy. Non-hormonal prescription options also exist for women who cannot take hormones.
How long before it works?
Hot flashes typically respond within a few weeks. Sleep and mood often take longer. Vaginal symptoms treated locally can take several weeks to improve and require continued use.
Can I stop suddenly?
Tapering is generally preferred over abrupt discontinuation, mainly because symptoms can return sharply. There is no fixed maximum duration; the decision to continue is reviewed periodically against your symptoms and your risk profile.
Does it cause weight gain?
The evidence does not support this. Weight and body composition change during the menopausal transition regardless of treatment, and some data suggests hormone therapy may attenuate the shift toward central fat rather than drive it.
The point
There is no threshold of suffering you must reach before your symptoms count. If they are affecting your sleep, your work, your relationships or your sense of yourself, that is sufficient reason to be assessed properly.
What a good assessment produces is not an automatic prescription. It is a clear picture of what is actually happening, including the possibility that something other than hormones is driving it, and a decision made against your own history rather than a general rule.
This article is for general information only and does not constitute medical advice. Symptoms and any treatment decision should be discussed with a qualified clinician who knows your full medical history.
